• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Bergman Alan B.

    4/6/26 5:56:49 PM ET
    $AIDX
    Precision Instruments
    Health Care
    Get the next $AIDX alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bergman Alan B.

    (Last)(First)(Middle)
    C/O 20/20 BIOLABS, INC.,
    15810 GAITHER ROAD, SUITE 235

    (Street)
    GAITHERSBURG MARYLAND 20877

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    20/20 Biolabs, Inc. [ AIDX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Financial Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    04/02/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option(1)$1.8804/02/2026A(1)100,000 (1)04/02/2036Common Stock100,000$0100,000D
    Explanation of Responses:
    1. 25,000 of the shares subject to the stock option will vest on the first anniversary of the date of grant and the remaining shares will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service to the Issuer.
    s/ Alan B. Bergman04/06/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $AIDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIDX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bergman Alan B.

    4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)

    4/6/26 5:56:49 PM ET
    $AIDX
    Precision Instruments
    Health Care

    SEC Form 4 filed by Zhou Jiming

    4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)

    4/6/26 5:56:27 PM ET
    $AIDX
    Precision Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Cohen Jonathan M

    4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)

    3/4/26 5:48:56 PM ET
    $AIDX
    Precision Instruments
    Health Care

    $AIDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

    Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that its OneTest™ multi-cancer early detection blood ("MCED") test has been selected as part of a firefighter cancer screening initiative for the state of Vermont in partnership with National Diagnostic Services ("NDS"). NDS will provide ultrasound services and medical oversight in

    5/27/26 8:31:00 AM ET
    $AIDX
    Precision Instruments
    Health Care

    20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

    Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed  GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced that it is developing contingency plans to establish Ebola and Hantavirus testing in its CAP-accredited CLIA laboratory if called upon to support or augment testing by public health laboratories. Early in the COVID-19 pandemic, 20/20 Biolabs was among the first companies in the U.S. to import, validate, and dis

    5/22/26 8:31:00 AM ET
    $AIDX
    Precision Instruments
    Health Care

    20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress

    State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent Strategic Wins Include Evexia Diagnostics Distribution Agreement, ROKIT Healthcare CKD License, and Commercial Launch of OneTest™ for Longevity GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the first quarter ended March

    5/20/26 4:05:00 PM ET
    $AIDX
    Precision Instruments
    Health Care

    $AIDX
    SEC Filings

    View All

    SEC Form PRE 14A filed by 20/20 Biolabs Inc.

    PRE 14A - 20/20 Biolabs, Inc. (0001139685) (Filer)

    6/1/26 4:40:25 PM ET
    $AIDX
    Precision Instruments
    Health Care

    20/20 Biolabs Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

    5/26/26 4:28:45 PM ET
    $AIDX
    Precision Instruments
    Health Care

    SEC Form 424B3 filed by 20/20 Biolabs Inc.

    424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)

    5/21/26 4:11:00 PM ET
    $AIDX
    Precision Instruments
    Health Care

    $AIDX
    Financials

    Live finance-specific insights

    View All

    20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress

    State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent Strategic Wins Include Evexia Diagnostics Distribution Agreement, ROKIT Healthcare CKD License, and Commercial Launch of OneTest™ for Longevity GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the first quarter ended March

    5/20/26 4:05:00 PM ET
    $AIDX
    Precision Instruments
    Health Care